The second patient was a 45-year-old Asian man. He was initially seen by dermatology with alopecia and a scaly rash on his face, elbow and hands. He was then diagnosed with early inflammatory arthritis and commenced steroids and methotrexate. He developed skin ulceration and respiratory symptoms with a CT chest showing features of COP. He was ANA negative but anti-Ro and anti-Scl-70 positive. He was given antibiotics, methylprednisolone and switched to mycophenolate mofetil. Whilst abroad he was admitted to hospital, diagnosed with anti-MDA5 positive amyopathic dermatomyositis and given methylprednisolone and cyclophosphamide. Cyclophosphamide was continued on his return to the UK, with PCP prophylaxis but he also required home oxygen. He was admitted to hospital with increasing breathlessness and given further methylprednisolone and treatment dose co-trimoxazole. Two weeks later he deteriorated further and repeat CT scan showed a pneumomediastinum. He received antibiotics, antifungals and rituximab but died after three days onITU. Discussion: Although in both cases it was recognised the patients had some form of inflammatory condition the diagnosis of anti-MDA5 positive dermatomyositis took some time. The lack of muscle involvement is typical and means clinicians need to give more thought to the possible diagnosis particularly when patients present with skin lesions and look specifically for MDA5 antibodies. These cases also show how rapidly the lung disease can progress. Being aware that a patient is MDA5 positive gives important information to the clinical team regarding the potential prognosis and in these cases it has been questioned whether these concerns were entirely relayed to the patients and their families. High serum ferritin, ground-glass opacities in all six lung fields and worsening of pulmonary infiltrates during therapy have been suggested as further poor prognosticfactors. Both patients presented particular challenges in trying to decide whether their deterioration was due to infection in the context of immunosuppression, disease progression or both and consequently full infection screens were performed including bronchoscopies at various points. Given how unwell both patients were all available treatments were considered. Once it was recognised how rapidly the lung disease was progressing they both received cyclophosphamide and rituximab. IV immunoglobulin was requested for both patients but only agreed for the first patient as he had proven PCP pneumonia. Key learning points: Anti-MDA5 positive dermatomyositis commonly presents with typical mucocutaneous lesions (such as cutaneous ulceration, alopecia and oral ulcers) which can differ from those seen in classical dermatomyositis. It is important to consider the possibility of anti-MDA5 positive dermatomyositisinapatientwithskinabnormalities andanormal CK, and in such circumstances request an extended myositis screen ensuring MDA5 is included. Patients who are MDA5 positive and have lung involvement often have rapidly progressive interstitial lung disease. Prognosis is especially poor when patients are admitted to ITU and worse than patients with anti-synthetase syndrome. Spontaneous pneumomediastinum can be a feature when the outcome is almost always poor in a ventilated patient. Treatment options are limited, generally aggressive immunosuppression is recommended when there is lung involvement and induction therapy with cyclophosphamide or rituximab has been tried. There are emerging reports of JAK inhibitors being used in dermatomyositis andso thismaybesomething toconsider inthis subsetof difficult to treat patients. Consideration should be given to vaccinating against influenza and pneumococcal infections as soon as possible, together with PCP prophylaxis and aggressive treatment of superadded infections. When appropriate patients and relatives should be made aware of the potentially poor prognosis. It is important to work closely with other specialities such as dermatology, respiratory and when necessary ITU. Due to the complexity and severityof this conditionan MDT approach is recommended.
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Rheumatology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom Introduction: Statins are a commonly used group of drugs which lowers low density lipoprotein (LDL) levels by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. Though they are effective and safe, about 0.1% patients on statins can develop severe myonecrosis orimmune mediated necrotising myopathy (IMNM). Here we present a case of IMNM secondary to atorvastatin exposure, resulting in severe muscle weakness and prolonged hospitalisation, and positive treatment response to intravenous immunoglobulin (IVIG).
Case description: A 59-year-old Caucasian lady with a history of hypothyroidism and hyperlipidaemia, presented with 5 weeks' history of progressive weakness in both upper and lower limbs which was preceded by flu like symptoms. She was also having swallowing difficulty and had neck-flexor weakness. There was MRC grade 2 power around hips, knees and shoulders, with normal power distally. She had been started on atorvastatin 10 mg6 months ago, which was stopped due to myalgia. She was admitted tothe hospital, andsoon developedrespiratorymuscle weakness. She had serial SVC assessment and required nasogastric feeding. Electromyography suggested myositis. MRI of the thighs showed extensive myositis, muscle biopsy confirmed necrotising myopathy. Autoantibodies were negative, but she had high titre HMGcoA reductase antibodies (anti-HMGCR). Creatine kinase levels on presentation was 24230 U/L, which increased to 31000 U/L. Initial SVC was 33% of predicted. CT scan of chest abdomen and pelvis did not reveal any malignancy. Cardiac MRI did not reveal myocarditis, though her troponin-T levels were raised1096 ng/L. She was non responsive to 3 pulses of 1 gm methyl-prednisolone. She was treated with IVIG, cyclophosphamide infusions and oral prednisolone. She made steady progress and was discharged with SVC of 70%, CK of 664 U/I, proximal muscle strength of 3/5 and feeding orally. She received 9cycles of 900 mgcyclophosphamide followed bymycophenolate mofetil 2gm/day. However, her CK levels plateaued to between 650 and 700; proximal lower limb power was fluctuating between 4 and 3. She received another course of IVIG-6 months after the onset of myositis which significantly improved her power, which sustained for around 4 months. The plan is to manage her with serialIVIG infusions. Discussion: Statins can cause adverse muscle related events, ranging from mild myalgia to severe myopathy and rhabdomyolysis. Rarely, patients can develop immune mediated necrotising myositis, as in our patient. IMNM can cause persisting myositis with predominantly proximal muscle weakness, and runs a protracted course. Statin-induced IMNM is associated with presence of anti HMGCR antibodies. There are no clinical trials to guide therapeutic decisions in IMNM, however some case series and observational studies have shown improvement with immunosuppression. IVIG have been shown to be effective in anti HMGCR associated IMNM, as inourcase. Even after stopping statins, IMNM can progress and patients can have prolonged weakness requiring immunosuppression. Around 50% patients continue to have significant weakness even after 2 years of treatment, indicating anunfavourable prognosis. Our patient continues to have waxing waning weakness with persistently raised CK, and IVIG infusions seems to give a rapid clinical response , though sustaining for 3 to 4 months, indicating a need for repeated infusions. The other treatment option remains rituximab, which has shown to have someefficacy inanti-SRP positive IMNM. Our patient had hypothyroidism, which is known to potentiate statin induced myopathy,however,strongassociationwithIMNMisnotestablished. Around 80% patients with anti HMGCR associated myositis have prior statin exposure, however, a subgroup of patients, especially among Asians, canhaveanti-HMGCRantibodyandmyositisevenwithoutstatinexposure. This indicates a possible a genetic susceptibility to statins. Also, exposure tooystermushroomandredyeastricehavebeenreportedtobeassociated withanti-HMGCRantibodiesinthissubgroupofpatients. Key learning points: Statins can cause muscle related adverse events. 2-11% patients can have mild myalgia and myopathy, however necrotising myopathy is extremely rare (0.1%). Anti-HMCGCR antibodies are associated with statin induced IMNM. IMNM has a protracted course and can continue for years after stopping statins. Long term Immunosuppression is required in IMNM. IVIG is effective in refractory cases. Anti-HMCGCR antibodies can be found in statin naïve patients. Hypothyroidism can potentiate statin induced myopathy. The risk of muscle injury is higher when taking a statin which is extensively metabolised by cytochrome P450 3A4 (CYP3A4) -like simvastatin and atorvastatin, with CYP3A4 inhibitors. Pravastatin, rosuvastatin are preferred in these cases.
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A PARANEOPLASTIC CASE OF DERMATOMYOSITIS
Harold Wilson-Morkeh 1 , and Maresa Carulli 1 1 Rheumatology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom Introduction: Dermatomyositis is a rare idiopathic autoimmune condition predominantly affecting women in their fifth or sixth decades. Both cutaneous manifestations and the symptoms of proximal muscle weakness are well described in the literature, and these can often be found in i2 26 September 2019 ORAL PRESENTATIONS the context of specific autoantibodies to aid diagnosis. The paraneoplastic subtype has been recognised for some time, notably in the absence of antisynthetase autoantibodies. More frequently, malignancies such as breast, ovarian and lung cancers as well as Hodgkin's lymphoma are implicated, though we present a rare case of metastatic melanoma recurrence associated with the known phenotype. Case description: A 35-year-old lady of British origin presented to the acute medical take with a 4-week history of progressive, symmetrical proximal weakness predominantly affecting her neck, shoulders, deltoids and hip flexors. She had textbook Gottron's papules overlying her metacarpophalangealjointsaswell asaheliotrope rash,V-signandshawl sign consistent with dermatomyositis. Her past medical history comprised superficial spreading melanoma, excised from skin over her right scapula5yearspreviously with noevidence of metastaticdisease onsentineloraxillary nodebiopsies.Shealsohadwell-controlled ulcerativecolitis and eczema. She took no regular medications and there was no relevant family history of note. Initial biochemistry revealed a significantly elevated creatine kinase just north of 7000, a correspondingly raised alanine aminotransferase, but normal acute phase reactants. Interestingly, all autoimmune serology, including a dedicated myositis immunoblot, was negative. This finding, in addition to her past medical history, raised the suspicion of a paraneoplastic phenomenon. Indeed, FDG-PET/CT demonstrated an intensely avid splenic lesion (maximum standardized uptake value, max-SUV 10.7) concerning for metastasis. A faintly avid left apical lung nodule and lower density lesions within the liver were also visualised and further elucidated on ensuing cross-sectional staging imaging and a dedicated MRI of the liver.
The FDG-PET/CT also highlighted moderate muscular uptake within the neck and upper limbs, whilst patchy high signal involving almost all muscle groups in both legs was seen on MRI in keeping with active inflammation. Subsequently, a right vastus lateralis muscle biopsy and an ultrasound-guided splenic biopsy were urgently performed without complication prior to initiation of intravenous methylprednisolone followed bya tapering course of oral prednisolone. Splenic histology revealed metastatic melanoma. After in-depth discussions with oncology the patient commenced encorafenib & binimetinib with marked symptomatic benefit. She continues to exhibit radiological and biochemical improvement to this day. Discussion:This is aninterestingand rare case. Ourreview of the existing literature found only 10 reports of melanoma presenting as paraneoplastic dermatomyositis. Melanoma is known to metastasise to the spleen, though it is extremely rare for it to be the first implicated site of spread. Rather, it is often a sign of multi-visceral involvement, and only found at post-mortem in the majority of cases. Evidently, therefore, stage IV malignant melanoma (distant metastases beyond regional lymph nodes) involving the spleen confers grave prognosis. This case demonstrates efficient use of the MDT leading to an accurate diagnosis and the swift initiation of effective treatment. Though it was initially felt the patient would require a splenectomy, the Oncologists and patient came to the shared decision that the use of BRAF and MEK inhibitors was preferable given the additional involved sites and the need to interrupt or delay dosing in the peri-operative period. Both agents selectively target key enzymes in the tumour-promoting MAPK pathway and initial signs are encouraging, with a repeat FDG-PET/CT a week into treatment demonstrating a significantly reduced metabolic activity in the spleen (SUV-max 3.5). The left apical lung nodule also appeared smaller onthe CT component and will continue tobe monitored. The muscle biopsy, largely academic in this context, should still garner interest. Perivascular lymphocytes were seen in both perimysium and endomysium leading to scattered atrophic fibres, though the perifascicular predilection that is highly characteristic of dermatomyositis was not observed in this case. However, immunohistochemistry in the paraffin sections demonstrated CD4 positive perivascular cells in the endomysium with no significant CD8 cells. This favourable ratio of CD4 is a hallmark of this subtype of idiopathic inflammatory myositis, in contrast with polymyositis where a CD8 infiltrate dominates. The lack of necrosis contrasts with another subtype, necrotising autoimmune myopathy. Key learning points: This case highlights a rare subtype of idiopathic inflammatory myositis with a characteristic phenotype. Negative autoantibodies should raise suspicion of paraneoplastic pathology and a comprehensive history and examination of the patient should be undertaken followed by appropriate diagnostic tests. It is important to note treatment of the underlying neoplasm led to a much greater degree of improvement in clinical symptoms, compared to conventional corticosteroid therapy. This is acommon theme described in the paraneoplasticsubtype. As aforementioned, it is rare for the spleen to be the first site of melanomatous metastatic spread. Splenic involvement is more commonly seen in the context of advanced disseminated disease which confers a poor prognosis. The estimated 5-year survival rate for stage IV disease is approximately 20%, though the use of novel targeted treatments and a relatively young age at diagnosis are just a couple of factors in this case that could lead to aconclusion that defies the odds. Obtaining histology in a swift manner is another key factor that can lead to improved outcomes, though the spleen has a rich vascular supply and thus biopsy carries a significant complication risk. Therefore, it should only be performedby highly experienced radiologistsor surgeons. The casealsoplaces emphasisontherole ofFDG-PET/CTas adiagnostic and prognostic tool. SUV-max figures aid interpretation but should always be compared with a physiological baseline as patient-related factors can vary. A SUV-max greater than 2.5 is generally indicative of malignancy though this level can also be seen in the context of infection or active inflammation so clinical correlation is always advised. Values in excess of 10,as inthis case, bear a high likelihood of aggressive disease.
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The authors declare no conflicts of interest. Introduction: Inflammatory muscle disease is a rare but well-recognised manifestation of systemic vasculitis. It can present as focal myositis or symmetrical proximal muscle involvement seen in polymyositis and dermatomyositis. Investigative findings in inflammatory myositis include raised creatine kinase, abnormal electromyography and muscle biopsy. MR scans can identify muscle abnormality, oedema, fibrosis and the extent of muscle involvement, and are routinely requested to evaluate patients with suspected or definite myositis. They also guide us to the appropriate muscles to biopsy. MR scans are not diagnostic of myositis and treating clinicians must be aware of its mimics. Our case demonstrates one such mimic. Case description: A 59-year-old male patient under care of the renal physicians for ANCA-associated vasculitis complained of bilateral thigh pain. He had completed IV cyclophosphamide therapy (CYCLOPs protocol) for vasculitis affecting lungs, kidneys, and ENT. He was taking 30mg prednisolone and 100mg azathioprine daily. He denied muscle weakness, paraesthesia, or sensory symptoms. There was no muscle wasting, fasciculation,or sensory loss. Deep tendon reflexes were normal. 8-months prior, he was investigated for right hip pain and paraesthesia with MR spine and right hip, and neurophysiological studies. Investigations confirmed lumbar disc prolapse with neurophysiology in keeping with right L4 denervation changes. He had been treated with physiotherapyand daily pregabalin, duloxetine, and co-codamol. Renal physicians requested MR thigh, which was reported as muscle oedema over the long length of the right vastus medialis and lateralis, suggesting myositis. Rheumatology referral for myositis related to vasculitis was made. He was PR3þve-3IU/ml (improved), ESR-2, CRP-4.6mg/L, CK-94U/L. EGFR remained stable at 66ml/min. Clinical features were not supportiveof myositis and systemic vasculitis was in remission.The decision was made to discuss scans at the rheumatology-radiology meeting before consideringa change in immunosuppression or muscle biopsy. Radiologists felt that findings of localised muscle group involvement suggested a neurogenic cause rather than primary muscle inflammation. They had reviewed MR lumbar spine donepreviously whichhad identified degenerative changes with right foraminal stenosis at L3-4 and L4-5 disc space. Electrophysiology showed chronic neurogenic changes of moderate severity in predominately L4 innervated muscles -vastus medialis and adductor magnus of the right lower limb. Findings were supportive of chronic right L4 radiculopathy and not a vasculitic neuropathy or myositis.
ALL THAT GLITTERS IS NOT GOLD
Hence immunosuppression was left unchanged. He responded well to physiotherapyand did not require spinal surgical intervention. Discussion: Our patient developed bilateral thigh pain in the setting of vasculitis. MR imaging was suggestive of myositis. Differential diagnoses included myositis related to vasculitis, primary focal myositis followed by vasculiticneuropathy, or denervation changes due to nerve entrapment. MRI is an excellent imaging modality for skeletal muscle due to its soft tissueresolution.It helps in narrowing differentials inskeletal muscle pathology, clinicians are able to identify individually affected muscle or muscle groups, give information about active muscle inflammation and/or damage. They can assist clinicians in targeting muscle for biopsy. Pattern and extent of muscle involvement can provide valuable clue to peripheral nerve orroot lesion. Though MR suggested myositis, clinical assessment was not typical of myositis. Our patient had no systemic features of active vasculitis, which
